Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP & CFO | October 28, 2013 | October 29, 2013 |
| Avantor, Inc.AVTR · Entity 3546 | Director | May 08, 2025 | May 12, 2025 |
| Bellerophon Therapeutics, Inc.BLPH · Entity 108982 | Director | March 31, 2021 | April 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date October 28, 2013 · Filed October 29, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,414 |
Reported balance
After 2013-10-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2013-10-28 · Tax withholding · Disposed 13,045 · Balance 94,414 F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 25,000 RSUs which fully vest on 10/28/2014; 10,586 RSUs which vest in one installment of 5,214 on 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2: These shares include 347 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 25,000 RSUs which fully vest on 10/28/2014; 10,586 RSUs which vest in one installment of 5,214 on 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These shares include 347 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Avantor, Inc.
Report date May 08, 2025 · Filed May 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 219,815 |
Reported balance
After 2025-05-08 transaction · row 1
1 source rowRow 1 · 2025-05-08 · Grant · Acquired 17,100 · Balance 219,815 F1: Reflects a grant of restricted stock units that vests on May 08, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 08, 2026.
Bellerophon Therapeutics, Inc.
Report date March 31, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,033 |
Reported balance
After 2021-03-31 transaction · row 1
1 source rowRow 1 · 2021-03-31 · Grant · Acquired 15,308 · Balance 157,033 F1: RSAs fully vested on grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSAs fully vested on grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kite Pharma, Inc.
Report date October 03, 2017 · Filed October 05, 2017
Section 16 reporting ended · disclosed 2017-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-10-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-09-13 · Gift · Disposed 635 · Balance 69,739 Row 2 · 2017-10-03 · Other · Disposed 67,932 · Balance 1,807 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Row 3 · 2017-10-03 · Disposition to issuer · Disposed 1,807 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2024-03-25 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F4: This option provided for vesting in 36 equal monthly installments commencing April 30, 2014. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.23 · Expires 2025-06-08 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F6: This option provided for vesting in 12 equal monthly installments following June 9, 2015. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.87 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-10-03 · Disposition to issuer · Disposed 7,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F7: This option provided for vesting in 12 equal monthly installments following June 1, 2016. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.21 · Expires 2027-06-19 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-10-03 · Disposition to issuer · Disposed 8,810 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F8: This option provided for vesting in 12 equal monthly installments following June 20, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes.
F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit.
F4: This option provided for vesting in 36 equal monthly installments commencing April 30, 2014.
F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option.
F6: This option provided for vesting in 12 equal monthly installments following June 9, 2015.
F7: This option provided for vesting in 12 equal monthly installments following June 1, 2016.
F8: This option provided for vesting in 12 equal monthly installments following June 20, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2025 Filed May 12, 2025 17:34 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 17,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-25-000152 · wk-form4_1747085662.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,815 F1 · kind: Reflects a grant of restricted stock units that vests on May 08, 2026. Read SEC document |
| April 28, 2025 Filed Apr 29, 2025 17:58 UTC | Avantor, Inc. AVTR · Entity 3546 | PurchaseCommon Stock | 8,091 | $12.81 | $103,645.71 |
DisclosureSEC source: 0001722482-25-000092 · wk-form4_1745963891.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,715 F1 · price: Represents the weighted average trading price of share purchased on the transaction date. The range for the purchase of the shares was $12.36 and $12.83. Read SEC document |
| May 09, 2024 Filed May 13, 2024 16:28 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 8,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-24-000114 · wk-form4_1715632120.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,624 F1 · kind: Reflects a grant of restricted stock units that vests on May 09, 2025. Read SEC document |
| May 11, 2023 Filed May 15, 2023 16:45 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 9,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-23-000117 · wf-form4_168418352647352.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,147 F1 · kind: Reflects a grant of restricted stock units that vests on May 11, 2024. Read SEC document |
| May 12, 2022 Filed May 16, 2022 18:13 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 6,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000124 · wf-form4_165273915693341.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,339 F1 · kind: Reflects a grant of restricted stock units that vests on May 12, 2023. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:59 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 1,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000086 · wf-form4_164919233594043.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,646 F1 · kind: Reflects a grant of restricted stock units that vests on May 11, 2022. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:10 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 15,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001827 · form4-04022021_040402.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,033 F1 · shares: RSAs fully vested on grant date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 17:38 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000099 · wf-form4_161463828573565.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,431 F1 · kind: Reflects a grant of restricted stock units that vests on February 25, 2022. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:29 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 11,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-20-000052 · wf-form4_158266972750413.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,195 F1 · kind: Reflects a grant of restricted stock units that vests on February 21, 2021. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 16:51 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001600132-20-000004 · wf-form4_158016184529637.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,225,920 Read SEC document |
| May 21, 2019 Filed May 22, 2019 11:14 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 20,000 | $0.61 | $12,198.00 |
DisclosureSEC source: 0001600132-19-000085 · wf-form4_155853806257021.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875,920 Read SEC document |
| May 21, 2019 Filed May 23, 2019 19:28 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionExisting Junior Convertible Preferred · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014603 · doc4.xml · derivative · entry 3 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 117,857 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Existing Junior Convertible Preferred Stock automatically converted into common stock of the Issuer upon consummation of the Issuer's initial public offering. The number of shares of common stock received upon conversion of the Existing Junior Convertible Preferred Stock was based on the aggregate liquidation preference of such stock divided by the initial public offering price of $14.00 per share. F2 · derivative.exercise_date: Existing Junior Convertible Preferred Stock automatically converted into common stock of the Issuer upon consummation of the Issuer's initial public offering. The number of shares of common stock received upon conversion of the Existing Junior Convertible Preferred Stock was based on the aggregate liquidation preference of such stock divided by the initial public offering price of $14.00 per share. F2 · derivative.expiration_date: Existing Junior Convertible Preferred Stock automatically converted into common stock of the Issuer upon consummation of the Issuer's initial public offering. The number of shares of common stock received upon conversion of the Existing Junior Convertible Preferred Stock was based on the aggregate liquidation preference of such stock divided by the initial public offering price of $14.00 per share. Read SEC document |
| May 21, 2019 Filed May 23, 2019 19:28 UTC | Avantor, Inc. AVTR · Entity 3546 | Exercise / conversionCommon Stock | 117,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-014603 · doc4.xml · nonDerivative · entry 2 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Existing Junior Convertible Preferred Stock automatically converted into common stock of the Issuer upon consummation of the Issuer's initial public offering. The number of shares of common stock received upon conversion of the Existing Junior Convertible Preferred Stock was based on the aggregate liquidation preference of such stock divided by the initial public offering price of $14.00 per share. Read SEC document |
| May 21, 2019 Filed May 23, 2019 19:28 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 14,286 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014603 · doc4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,144 F1 · kind: Reflects a grant of restricted stock units that vests on May 21, 2020. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 16:21 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 714,286 | $0.70 | $500,000.20 |
DisclosureSEC source: 0001600132-19-000043 · wf-form4_154845128913147.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,855,920 Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:21 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 227,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001600132-19-000042 · wf-form4_154845124603583.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141,634 Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 17:40 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 99,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001600132-18-000044 · wf-form4_152279163964980.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914,361 Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 8,810 | $88.79 Strike: $91.21 | $782,239.90 |
DisclosureSEC source: 0001209191-17-056240 · doc4.xml · derivative · entry 7 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,810 shares Expires 2027-06-19 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F8 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 20, 2017. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 7,000 | $129.13 Strike: $50.87 | $903,910.00 |
DisclosureSEC source: 0001209191-17-056240 · doc4.xml · derivative · entry 6 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2026-05-31 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F7 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 1, 2016. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 10,000 | $120.77 Strike: $59.23 | $1,207,700.00 |
DisclosureSEC source: 0001209191-17-056240 · doc4.xml · derivative · entry 5 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-08 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F6 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 9, 2015. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 50,000 | $178.65 Strike: $1.35 | $8,932,500.00 |
DisclosureSEC source: 0001209191-17-056240 · doc4.xml · derivative · entry 4 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-03-25 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F4 · derivative.exercise_date: This option provided for vesting in 36 equal monthly installments commencing April 30, 2014. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerCommon Stock | 1,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-056240 · doc4.xml · nonDerivative · entry 3 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3 · price: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | OtherCommon Stock | 67,932 | $180.00 | $12,227,760.00 |
DisclosureSEC source: 0001209191-17-056240 · doc4.xml · nonDerivative · entry 2 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,807 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 16:06 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 248,962 | Not disclosed Strike: $1.24 | Not disclosed |
DisclosureSEC source: 0001600132-17-000111 · wf-form4_150706118735432.xml · derivative · entry 2 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,962 Underlying: Common Stock · 248,962 shares Expires 2022-09-29 F1 · price: The reported securities are included within Units purchased by the reporting person for $1.205 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 16:06 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 248,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001600132-17-000111 · wf-form4_150706118735432.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,351 F1 · price: The reported securities are included within Units purchased by the reporting person for $1.205 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 16:54 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001600132-17-000100 · wf-form4_150645922823895.xml · derivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-09-21 F1 · derivative.exercise_date: This option was granted on September 22, 2017. This option vests in three equal annual installments over a three-year period from the date of grant. Read SEC document |
| September 13, 2017 Filed Oct 5, 2017 20:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GiftCommon Stock | 635 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056240 · doc4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,739 Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 18:44 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 57,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001600132-17-000068 · wf-form4_149886264409131.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,389 Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 14:34 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,810 | $0.00 Strike: $91.21 | $0.00 |
DisclosureSEC source: 0001209191-17-041302 · doc4.xml · derivative · entry 2 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,810 Underlying: Common Stock · 8,810 shares Expires 2027-06-19 F1 · derivative.exercise_date: The stock option shall vest in 12 successive equal monthly installments following the date of grant. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 14:34 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GrantCommon Stock | 2,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041302 · doc4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,374 Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 16:28 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 588,373 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001628280-16-021961 · wf-form4_148131892234661.xml · derivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,373 Underlying: Common Stock · 588,373 shares Expires 2026-12-06 F1 · derivative.exercise_date: The option grant was approved by Bellerophon Therapeutics, Inc.'s board of directors on December 7, 2016, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 15:31 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 285,715 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001628280-16-021725 · wf-form4_148053789553674.xml · derivative · entry 2 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,715 Underlying: Common Stock · 285,715 shares Expires 2021-11-29 F1 · price: The reported securities are included within 285,715 Class A Units purchased by the reporting person for $0.70 per Class A Unit. Each Class A Unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 15:31 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 285,715 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-16-021725 · wf-form4_148053789553674.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,417 F1 · price: The reported securities are included within 285,715 Class A Units purchased by the reporting person for $0.70 per Class A Unit. Each Class A Unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 22:22 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 13,045 | $116.32 | $1,517,394.40 |
DisclosureSEC source: 0001127602-13-029956 · form4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,414 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 25,000 RSUs which fully vest on 10/28/2014; 10,586 RSUs which vest in one installment of 5,214 on 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 347 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 22:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,721 | $104.93 | $285,514.53 |
DisclosureSEC source: 0001127602-13-014711 · form4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,312 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 50,000 RSUs which vest in two equal annual installments of 25,000 each commencing 10/28/2013; 10,586 RSUs which vest in one installment of 5,214 on 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 200 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2013 Filed Jan 31, 2013 01:18 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 7,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-003262 · form4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,950 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 50,000 RSUs which vest in two equal annual installments of 25,000 each commencing 10/28/2013; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| October 28, 2012 Filed Oct 30, 2012 00:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 11,671 | $87.63 | $1,022,729.73 |
DisclosureSEC source: 0001127602-12-029209 · form4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,438 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 50,000 RSUs which vest in two equal annual installments of 25,000 each commencing 10/28/2013; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 82 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2012 Filed May 2, 2012 01:02 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 8,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-015259 · form4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,027 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 75,000 RSUs which vest in three equal annual installments of 25,000 each commencing 10/28/2012; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| October 28, 2011 Filed Oct 31, 2011 23:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 10,427 | $58.06 | $605,391.62 |
DisclosureSEC source: 0001127602-11-028022 · form4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,373 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 75,000 RSUs which vest in three equal annual installments of 25,000 each commencing 10/28/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 01:16 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 55,125 | $54.69 Strike: $54.69 | $3,014,786.25 |
DisclosureSEC source: 0001127602-11-013890 · form4.xml · derivative · entry 2 Peacock Jonathan M · CIK 0001500241 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,125 Underlying: Common Stock · 55,125 shares Expires 2021-04-25 F3 · derivative.exercise_date: These non-qualified stock options are exercisable in three annual installments of 33%, 33% and 34% on 4/25/2013, 4/25/2014 and 4/25/2015, respectively. Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 01:16 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 15,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-013890 · form4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,800 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/25/2013, 4/25/2014 and 4/25/2015, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 100,000 RSUs which vest in four equal annual installments of 25,000 each commencing 10/28/2011; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| October 28, 2010 Filed Oct 30, 2010 00:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 175,000 | $57.27 Strike: $57.27 | $10,022,250.00 |
DisclosureSEC source: 0001127602-10-026242 · form4.xml · derivative · entry 2 Peacock Jonathan M · CIK 0001500241 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2020-10-28 F2 · derivative.exercise_date: These options are exercisable in four equal annual installments of 25% each commencing October 28, 2011. Read SEC document |
| October 28, 2010 Filed Oct 30, 2010 00:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-10-026242 · form4.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Company's 2009 Equity Incentive Plan and vest in four equal annual installments of 25% each commencing October 28, 2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.